Yellow Fever Vaccine, Singapore
Yellow Fever Vaccine, Singapore @beautysingapore_com: Live attenuated yellow fever virus vaccine jab/shot/injection schedule, to vaccinate against the Yellow fever virus, to immunise against Yellow fever
The 17D vaccine, which is based on a live, attenuated viral strain, is the only commercially available yellow fever vaccine. It is given as a single subcutaneous (or intramuscular) injection. Yellow fever vaccine is highly effective (approaching 100%). All individuals aged 9 months or older and living in countries or areas at risk should receive yellow fever vaccine.
Precautions and contraindications
With the exception of very rare cases of vaccine-associated neurotropic and viscerotropic disease (see below), the 17D vaccine is generally considered to be safe. However, some vaccine recipients develop mild systemic reactions, including myalgia and headache. Contraindications include true allergy to egg protein, immunodeficiency (congenital or acquired) and symptomatic HIV infection (Chapter 9). There is a theoretical risk of harm to the fetus if the vaccine is given during pregnancy and vaccination of nursing mothers should be avoided because of the risk for the transmission of 17D virus to and encephalitis in the breast-fed infant.These risks must be weighed against the risk to the mother of remaining unvaccinated and travelling to an area where exposure to YFV may occur. In general, unvaccinated pregnant or nursing women should be advised not to travel to such areas.
Hypersensitivity reactions are rare, particularly anaphylactic reactions. However, the vaccine is produced in embryonated chicken eggs and is contraindicated in persons with a history of oral egg intolerance or strong allergic reactions to egg-based products.
Encephalitis has been reported as a rare event following vaccination, principally in infants under 6 months of age. As a result, the vaccine is contraindicated in infants under 6 months of age and is not recommended for those aged 6–8 months, except during epidemics when the risk of YFV transmission may be very high.
Vaccine-associated viscerotropic disease is a recently described adverse event that on very rare occasions has occurred after the first immunization with the yellow fever 17D vaccine. Onset is within 10 days of vaccination and the pathological process is characterized by severe multi-organ failure and an overall case—fatality rate in excess of 60%. Known risk factors include a history of thymus disease (e.g. thymoma or thymectomy) and age ≥ 60 years. In the United Sates, the risk for people aged ≥ 70 years of contracting viscerotropic disease after receiving vaccination against yellow fever is estimated to be 2.4 cases/100 000 vaccine doses.
Increased incidence of vaccine-associated neurotropic disease (e.g. meningoencephalitis, acute disseminated encephalomyelitis and Guillain-Barré syndrome) has been reported in infants under 6 months of age and in vaccine recipients aged ≥60 years . The reported rate of vaccine-associated neurotropic disease in travellers from the United States and Europe ranges between 0.13 and 0.8 per 100 000 doses.
Yellow fever vaccination is required for travellers to certain countries and recommended for all travellers to countries or areas with risk of yellow fever transmission (see Country list and Annex 1). The risk to unvaccinated individuals who visit countries or areas where there may be yellow fever transmission is often greater than the risk of a vaccine-related adverse event. While yellow fever vaccination should be encouraged as a key prevention strategy, it is important to screen travel itineraries and carefully evaluate the potential risk of systemic illness after yellow fever vaccination. Great care should be exercised not to prescribe yellow fever vaccination to individuals who are not at risk of exposure to infection, based on an accurate assessment of the travel itinerary. Although vaccination is generally not recommended for travellers going to areas where the risk of exposure is low, any risk (e.g. as a result of prolonged travel or heavy exposure to mosquito bites) should be weighed against individual risk factors for vaccine-associated adverse events (e.g. altered immune status).
| Type of vaccine: Live, attenuated |
Number of doses: One dose of 0.5 ml
Booster: Currently every 10 years (if re-certification is needed)
Contraindications: Infants aged less than 6 months; history of allergy to egg or to any of the vaccine components, or hypersensitivity to a previous dose of the vaccine; thymoma or history of thymectomy, immunodeficiency from medication, disease or symptomatic HIV infection.
Adverse reactions: Rarely, neurological (encephalitis) or multi-organ failure resembling wild-type yellow fever
Before departure: International certificate of vaccination becomes valid 10 days after vaccination.
Recommended for: All travellers to countries and areas with risk of yellow fever transmission and when required by countries.
Special precautions: Not recommended for infants aged 6-8 months, except during epidemics when the risk of YF virus transmission may be very high. The risks and benefits of vaccination in this age group should be carefully considered before vaccination. The vaccine should be avoided during pregnancy or breastfeeding. However, pregnant or nursing women may be vaccinated during epidemics or if traveling to country or area a risk of transmission is unavoidable.
| Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic: |
| SHIM CLINIC|
168 Bedok South Avenue 3 #01-473
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Yellow Fever Vaccine, Singapore
| Opening Hours |
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.
Meningitis vaccine withstands African heat without damage
Wed, 19 Feb 2014 11:23:23 +0100 | Guardian Unlimited Science
MenAfriVac can be used effectively at 40C and below, raising hopes for yellow fever and cholera immunisation campaignsThe first immunisation campaign in Africa using a vaccine that does not have to be stored in fridges and iceboxes has been successful and substantially cut costs, according to scientists.MenAfriVac is authorised for use at temperatures not exceeding 40C and can be kept out of the fridge for up to four days. The vaccine against meningitis A was unusual in being designed specifically for the African meningitis belt, where annual epidemics used to kill thousands, but experts say it would be feasible to allow other vaccines to be used outside of cold-chain conditions. Vaccines against yellow fever and cholera are among those that could potentially be kept and used safely at hig...
Challenges and solutions for a rational vaccine design for TB-endemic regions.
Tue, 04 Feb 2014 00:00:00 +0100 | Critical Reviews in Microbiology
Authors: Gowthaman U, Mushtaq K, Tan AC, Rai PK, Jackson DC, Agrewala JN
A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available.
Tue, 28 Jan 2014 00:00:00 +0100 | Vaccine
Authors: Ishikawa T, Yamanaka A, Konishi E
Yellow fever vaccine for patients with HIV infection.
Thu, 23 Jan 2014 05:00:00 +0100 | Cochrane Database of Systematic Reviews
CONCLUSIONS: YF vaccination can produce protective levels of neutralising antibodies in HIV patients. Immunogenicity of YF vaccine is slightly less in HIV-infected patients compared to HIV-uninfected patients. No serious adverse events related to YF vaccine were observed in HIV-infected study participants. At time of immunisation, higher CD4 cell counts and lower HIV RNA levels in patients with HIV infection seem to be key determinants for development of protective titres of neutralising antibodies. The quality of the evidence for all outcomes was low to very low. YF vaccine may potentially be used safely in HIV-infected patients, although our conclusions are limited by small numbers of patients who have been reported. To assure maximum effectiveness YF vaccine should be given to HIV-infec...
Pre-Travel Preparation of US Travelers Going Abroad to Provide Humanitarian Service, Global TravEpiNet 2009-2011.
Mon, 20 Jan 2014 05:00:00 +0100 | The American Journal of Tropical Medicine and Hygiene
Authors: Stoney RJ, Jentes ES, Sotir MJ, Kozarsky P, Rao SR, Larocque RC, Ryan ET, the Global TravEpiNet Consortium
Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
Mon, 20 Jan 2014 05:00:00 +0100 | Vaccine
Authors: Biscayart C, Carrega ME, Sagradini S, Gentile A, Stecher D, Orduna T, Bentancourt S, Jiménez SG, Flynn LP, Arce GP, Uboldi MA, Bugna L, Morales MA, Digilio C, Fabbri C, Enría D, Diosque M, Vizzotti C
[Report] Vaccine Activation of the Nutrient Sensor GCN2 in Dendritic Cells Enhances Antigen Presentation
Fri, 17 Jan 2014 02:50:14 +0100 | Science: Current Issue
The success of the yellow fever vaccine is linked to the amino acid starvation pathway, which promotes adaptive immunity.
Trend in proportions of missed children during polio supplementary immunization activities in the African Region: Evidence from independent monitoring data 2010-2012.
Mon, 13 Jan 2014 05:00:00 +0100 | Vaccine
Authors: Okeibunor J, Gasasira A, Mihigo R, Salla M, Poy A, Orkeh G, Shaba K, Nshimirimana D
Defining Risk Groups to Yellow Fever Vaccine-Associated Viscerotropic Disease in the Absence of Denominator Data.
Mon, 06 Jan 2014 05:00:00 +0100 | The American Journal of Tropical Medicine and Hygiene
Authors: Seligman SJ, Cohen JE, Itan Y, Casanova JL, Pezzullo JC
Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.
Fri, 03 Jan 2014 05:00:00 +0100 | Antiviral Research
In this study we tested the prophylactic and therapeutic efficacy of this MAb against virulent YFV infection in an immunocompetent hamster model. Intraperitoneal (ip) administration of a single dose of MAb 2C9-cIgG 24h prior to YFV challenge resulted in significantly improved survival rates in animals treated with 380 or 38μg of MAb compared to untreated animals. Treatment with the higher dose also resulted in significantly improved weight gain and reductions in serum alanine aminotransferase (ALT) and virus titers in serum and liver. Prophylactic treatment with 2C9-cIgG 24h prior to virus challenge prevented the development of a virus-neutralizing antibody (vnAb) response in hamsters. Administration of a single ip dose of 380μg of 2C9-cIgG as late as 72h post-YFV challenge also resulted...